



**Company Contact:**  
**Richard Gabriel**  
**CEO and President**  
**941 366-3400**  
**-or-**  
**Ron Stabiner**  
**The Wall Street Group, Inc.**  
**212-888-4848**

**FOR IMMEDIATE RELEASE:**

**DNAPRINT GENOMICS APPOINTS KAREN L. SURPLUS  
AS NEW CHIEF FINANCIAL OFFICER**

**SARASOTA, Fla., June 29, 2006 – DNAPrint Genomics, Inc. (OTCBB: DNAG)** today announced the appointment of Karen L. Surplus as the Company’s new Chief Financial Officer.

Ms. Surplus, whose appointment is effective immediately, fills the position formerly held by Monica Tamborini, who is retiring.

“I personally want to thank Monica for the dedicated service she has provided to the Company, and at the same time welcome Karen to our Management Team,” stated DNA Print Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph. D.

DNAPrint Founder and Chief Scientific Officer Tony F. Frudakis stated: “Monica’s retirement is a loss for DNAPrint, and we are sad to see her go. We feel fortunate to have found someone as experienced as Karen to fill this key position.”

“Karen maintains a broad portfolio of expertise in corporate finance that will easily blend into the fast-paced environment of DNAPrint Genomics,” stated President and Chief Executive Officer Richard Gabriel. “She is an all-around financial executive whose skills in providing fiscal guidance will be a valuable asset as the newest member of the Company’s management team.”

Ms. Surplus is a certified public accountant who has operated her own financial consulting business for the past three years. Previously, she served as CFO of Digital Fusion, Inc. (DIGF: OB), based in Huntsville, Ala., from 1999-2003, and was Chief Accounting Officer at Tampa-based PowerCerv Corp., from 1995-1999. From 1988-1995, she held the position of Controller and Treasurer of Progress Credit Corporation, a subsidiary of Progress Energy (NYSE: PGN), based in Raleigh, N.C. In addition, she worked at Progress Energy and its subsidiaries as internal auditor and senior accountant from 1985-1988. She also previously served as a senior auditor with Arthur Andersen & Company, Kansas City, from 1981-1985.

Ms. Surplus received a B.S. in Business, majoring in accounting, from Kansas State University in 1981, and graduated from the University of Tampa with an MBA in May 1992.

**About DNAPrint Genomics, Inc.**

DNAPrint Genomics, Inc. ([www.dnaprint.com](http://www.dnaprint.com)) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and

(MORE)

clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to [www.dnaprint.com](http://www.dnaprint.com) for information on law enforcement and consumer applications which include DNAWitness (TM), RETINOME(TM), AncestryByDNA(TM) and EuroDNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

### **Forward-Looking Statements**

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

###